About OculisOculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye.
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
Founders: Einar Stefansson, MD, PhD and Thorsteinn Loftsson, PhD
CEO: Pall Ragnar Johnnesson
CCO: (Regulatory and Clinical) Gudrun Marta Asgrimsdottir, MSc
CSO: Thorsteinn Loftsson, PhD
Please click here for.
Please click here for clinical trial information.
Tweets by Amgen
15 articles with Oculis
Oculis appoints David Jacobs, M.D. as Chief Development Officer adding complementary drug development and regulatory expertise
Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, announces the appointment of David Jacobs, M.D., as Chief Development Officer.
10/8/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Oculis announces presentation of positive results from Phase 2 trial of OCS-01 in patients with Diabetic Macular Edema (DME) at EURETINA 2020 Virtual
The study met its pre-specified efficacy endpoints and showed that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME No significant unanticipated ocular adverse events were observed Phase 3 trial for OCS-01 in DME is in preparation following positive End-of-Phase 2 meeting with FDA Results were presented by renowned retina specialist Prof. Ramin Tadayoni, M.D., Ph.D. LAUSANNE, Switzerland, Oct. 05, 2020
9/24/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications
Oculis S.A., a biopharmaceutical company focused on developing transformative topical (eye drop) ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for OCS-01 in two indicat
Oculis Reports Positive Top-line Data From SKYGGN (Phase 2) Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery
- OCS-01 meets primary endpoints demonstrating superior efficacy and safety vs vehicle in the treatment of inflammation and pain following cataract surgery with a once-daily regimen - SKYGGN is the second positive trial with OCS-01 highlighting its potential for treating both front-of-the-eye and retinal diseases such as DME - Positive results validate the Solubilizing NanoParticle (SNP) formulation technology in developing topical treatments for front-of-the-eye with less fr
Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery at Upcoming ASCRS Annual Meeting 2020
Oculis S.A. announces that a presentation of results from its Phase 2 clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, will be made at the American Society of Cataract and Refractive Surgery Annual Meeting, which will be held online on May 16-17, 2020.
3/6/2020Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week's Movers & Shakers.
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments for ophthalmic diseases, announced the appointment of Marcia de Souza Lima, M.D., M.I.P.P., as Chief Medical Officer.
2/17/2020It was a very busy week for clinical trial news. Here’s a look.
10/14/2019It was a busy week for clinical trial announcements. Here’s a look.
Oculis Strengthens its Global Clinical and Business Development Capabilities through Strategic Appointments to Senior Management Team
Oculis announces the appointments of Fabio Baschiera PharmD, MPh, Ph.D. as Vice President of Clinical Development, and Louie-Anne Gauthier M.Sc., as Vice President of Strategic Marketing, Business Development and Licensing.
Oculis appoints World-renowned Ophthalmology Specialist Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board
Oculis, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings extensive clinical experience.
Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases
The financing was led by a syndicate of leading international life science investors including Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners.